L
Lin Wu
Researcher at Hoffmann-La Roche
Publications - 101
Citations - 2796
Lin Wu is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 40 publications receiving 1693 citations.
Papers
More filters
Journal ArticleDOI
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok,Yi-Long Wu,Jin Soo Lee,Chong-Jen Yu,Virote Sriuranpong,Jennifer Sandoval-Tan,Guia Ladrera,Sumitra Thongprasert,Vichien Srimuninnimit,Meilin Liao,Yunzhong Zhu,Caicun Zhou,Fatima Fuerte,Benjamin Margono,Wei Wen,Julie Tsai,Matt Truman,Barbara Klughammer,David S. Shames,Lin Wu +19 more
TL;DR: Analysis of matched tumor and blood samples from the FASTACT-2 study suggests blood-based circulating-free tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC and dynamic changes in cfDNA EGFR mutations relative to baseline may predict clinical outcomes.
Journal ArticleDOI
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Qing Zhou,Yi-Long Wu,Siyu Wang,Jian Hu,Wei Liu,Wei Li,Jianhua Shi +31 more
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.
Journal ArticleDOI
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Yi-Long Wu,Shun Lu,Ying Cheng,Caicun Zhou,Jie Wang,Tony Mok,Li Zhang,Hai Yan Tu,Lin Wu,Jifeng Feng,Yiping Zhang,Alexander Luft,Jianying Zhou,Zhiyong Ma,You Lu,Chengping Hu,Yuankai Shi,Christine Baudelet,Junliang Cai,Jianhua Chang +19 more
TL;DR: This is the first phase III study in a predominantly Chinese population reporting results with a programmed death 1 inhibitor and nivolumab improved OS versus docetaxel and results were consistent with global CheckMate 017 and 057 studies.
Journal ArticleDOI
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib
TL;DR: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer during treatment with erlotinib and its relation to disease progression was investigated.
Journal ArticleDOI
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich,Jonathan H. Goldman,Jong-Mu Sun,Elaina Mann,Lecia V. Sequist,Krzysztof Konopa,Wei Wen,Philipp Angenendt,Leora Horn,David R. Spigel,Jean-Charles Soria,Benjamin Solomon,D. Ross Camidge,Shirish M. Gadgeel,Cloud P. Paweletz,Lin Wu,Sean Chien,Patrick O'Donnell,Shannon Matheny,Darrin Despain,Lindsey Rolfe,Mitch Raponi,Andrew R. Allen,Keunchil Park,Heather A. Wakelee +24 more
TL;DR: The findings suggest the cobas and BEAMing plasma tests can be useful tools for noninvasive assessment and monitoring of the T790M resistance mutation in NSCLC, and could complement tumor testing by identifying T790m mutations missed because of tumor heterogeneity or biopsy inadequacy.